Sanofi SA

SNW

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from cardiometabolic will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs, with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    82,878

Stocks News & Analysis

stocks

New ASX share on our best ideas list

This undervalued miner is unappreciated by the market.
stocks

Has the most hated company on the ASX 200 bounced back?

Encouraging results indicate a potential turnaround story.
stocks

Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown

We think Amazon stock looks attractive.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,922.004.900.05%
CAC 407,608.7362.570.83%
DAX 4023,747.11321.141.37%
Dow JONES (US)43,588.58542.40-1.23%
FTSE 1009,105.3836.800.41%
HKSE24,733.45225.640.92%
NASDAQ20,650.13472.31-2.24%
Nikkei 22540,290.70508.90-1.25%
NZX 50 Index12,684.0445.36-0.36%
S&P 5006,238.010.000.00%
S&P/ASX 2008,663.701.700.02%
SSE Composite Index3,583.3123.360.66%

Market Movers